SMO Business Achieves Full-Year Operating Profitability
First written in FY2017-Q1. 1 of 4 entries say "Restated". Latest entry: FY2017.
No other company in this theme has enough history to compare yet.
- FY2017DroppedAnnual report
「We transferred our subsidiary engaged in the SMO business in June 2017. Going forward, we will concentrate management resources on our core business, work to create an environment in which technical employees can remain active throughout their careers, raise the level of our professional technical services, strengthen our corporate foundation over the medium to long term and enhance corporate value.」
The target of achieving full-year operating profitability in the SMO business was withdrawn as an ongoing Company theme after the Company reported a full-year operating loss and transferred the subsidiary. - FY2017-Q3SoftenedAnnual report
「The Company will seek to increase revenue through progress in clinical trials and the acquisition of new projects, among other factors, and achieve operating profitability for the full year.」
The target of full-year operating profitability has been maintained, but the wording has changed from “expects to be operating-profit positive” through the previous quarter to wording stating that the Company will seek to achieve it. - FY2017-Q2RestatedAnnual report
「Revenue is expected to increase through progress in clinical trials and the acquisition of new projects, among other factors, and the Company expects to be operating-profit positive for the full year.」
The Company continues to pursue a policy of expecting full-year operating profitability in the SMO business through progress in clinical trials and the acquisition of new projects. - FY2017-Q1First statedAnnual report
「Revenue is expected to increase through progress in clinical trials and the acquisition of new projects, among other factors, and the Company expects to be operating-profit positive for the full year.」
The Company expects the SMO business to achieve full-year operating profitability through progress in clinical trials and the acquisition of new projects.